Adaptive Sampling Advances Pediatric Cancer Profiling - Summary - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Adaptive Sampling Advances Pediatric Cancer Profiling

  • November 16, 2026

  • 3 min

Share

Objective:

Evaluate whether nanopore whole-genome sequencing with adaptive sampling (AS-WGS) can detect clinically relevant genomic alterations and support tumor classification in pediatric cancers.

Approach:
  • Study samples: Researchers analyzed 36 samples from 35 pediatric patients, including 31 tumor samples from patients with leukemia and solid cancers.
  • Sequencing and analysis: Nanopore whole-genome sequencing with adaptive sampling (AS-WGS) targeted approximately 380 clinically relevant genomic regions while retaining genome-wide information. The team developed the open-source nf-core-oncoseq pipeline to analyze data during sequencing.
  • Comparison: The researchers compared AS-WGS results with conventional diagnostic testing and used DNA methylation information for tumor classification.
Key Findings:
  • Compared with conventional diagnostic testing, AS-WGS detected all 20 previously identified gene fusions, mutations in 58 of 59 affected genes, and 20 of 21 large copy-number alterations.
  • The assay detected mutations present in as little as 5% of sequenced DNA.
  • Within 24 hours, all 20 gene fusions and all 47 evaluated mutations with variant allele frequencies above 25% had at least five supporting reads. Large chromosomal alterations could be identified within the first hour.
  • Methylation-based analysis correctly classified 9 of 11 acute lymphoblastic leukemia samples and 8 of 12 solid tumors.
  • Researchers estimated sequencing costs at approximately CAD $1,700 per sample, compared with more than CAD $5,000 for combined conventional approaches.
Interpretation:

The study authors reported that AS-WGS provided early findings on clinically relevant alterations and combined detection of major genomic alteration classes with methylation-based tumor classification in one workflow.

Limitations:
  • Some variants required manual review, and low-frequency mutation detection could require 72 hours of sequencing.
  • DNA quality and sequencing performance affected results.
  • Further clinical validation is needed to determine whether AS-WGS can replace existing diagnostic workflows and improve treatment decisions.
Conclusion:

In this pediatric cancer sample set, AS-WGS detected many clinically relevant genomic alterations, with some findings available within hours, and supported methylation-based tumor classification.

Sources:

Original Source(s)

Related Content